文献速递胸部CT

深度学习影像组学列线图术前鉴别胸腺上皮肿瘤组织学亚型

Development and validation of a deep learning radiomics nomogram for preoperatively differentiating thymic epithelial tumor histologic subtypes.
PubMed 文献 · Eur Radiol · 2023-05-06

本研究基于增强CT提取深度学习特征构建深度学习影像组学列线图(DLRN),用于术前预测胸腺上皮肿瘤(TET)风险状态。多中心纳入257例经手术病理证实的TET患者,DLRN结合临床特征、主观CT征象和深度学习特征,在训练集及验证集中AUC达0.846-0.959,显示高性能预测能力。

要点

  • DLRN结合增强CT深度学习特征与主观CT征象(如浸润),可术前区分低风险(A、AB、B1)与高风险(B2、B3、C)TET。
  • 外部验证AUC分别为0.846(95%CI 0.750-0.942)和0.846(95%CI 0.735-0.957),提示模型泛化能力良好。
  • 准确评估风险状态可能辅助决定术前是否需要新辅助治疗。

核心结论

  • DLRN由增强CT来源的深度学习特征和主观CT征象组成,在预测TET患者风险状态方面表现出高性能。
  • DLRN在区分TET风险状态方面优于深度学习特征、影像组学特征或临床模型。

研究设计与样本

  • 使用基于Transformer的卷积神经网络从所有病灶提取深度学习特征,通过选择算子回归和最小绝对收缩法构建深度学习特征(DLS)。
  • 参考标准为手术病理证实的TET组织学亚型,低风险包括A、AB、B1亚型(116例),高风险包括B2、B3、C亚型(141例)。

关键影像表现/征象

  • 主观CT征象中的浸润表现与DLS结合在区分TET风险状态方面表现最佳。

诊断标准与关键数值

  • 从116例低风险TET和141例高风险TET中选出25个非零系数的深度学习特征构建DLS。
  • DLRN在训练集、内部验证集、外部验证集1和2的AUC分别为0.959(95%CI 0.924-0.993)、0.868(95%CI 0.765-0.970)、0.846(95%CI 0.750-0.942)和0.846(95%CI 0.735-0.957)。

临床应用与阅片要点

  • DLRN可用于术前无创预测TET病理风险状态,辅助治疗决策和个体化治疗。
  • 阅片时需关注CT征象中的浸润表现,并结合深度学习特征进行综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Using contrast-enhanced computed tomography (CECT) and deep learning technology to develop a deep learning radiomics nomogram (DLRN) to preoperative predict risk status of patients with thymic epithelial tumors (TETs).

METHODS: Between October 2008 and May 2020, 257 consecutive patients with surgically and pathologically confirmed TETs were enrolled from three medical centers. We extracted deep learning features from all lesions using a transformer-based convolutional neural network and created a deep learning signature (DLS) using selector operator regression and least absolute shrinkage. The predictive capability of a DLRN incorporating clinical characteristics, subjective CT findings and DLS was evaluated by the area under the curve (AUC) of a receiver operating characteristic curve.

RESULTS: To construct a DLS, 25 deep learning features with non-zero coefficients were selected from 116 low-risk TETs (subtypes A, AB, and B1) and 141 high-risk TETs (subtypes B2, B3, and C). The combination of subjective CT features such as infiltration and DLS demonstrated the best performance in differentiating TETs risk status. The AUCs in the training, internal validation, external validation 1 and 2 cohorts were 0.959 (95% confidence interval [CI]: 0.924-0.993), 0.868 (95% CI: 0.765-0.970), 0.846 (95% CI: 0.750-0.942), and 0.846 (95% CI: 0.735-0.957), respectively. The DeLong test and decision in curve analysis revealed that the DLRN was the most predictive and clinically useful model.

CONCLUSIONS: The DLRN comprised of CECT-derived DLS and subjective CT findings showed a high performance in predicting risk status of patients with TETs.

CLINICAL RELEVANCE STATEMENT: Accurate risk status assessment of thymic epithelial tumors (TETs) may aid in determining whether preoperative neoadjuvant treatment is necessary. A deep learning radiomics nomogram incorporating enhancement CT-based deep learning features, clinical characteristics, and subjective CT findings has the potential to predict the histologic subtypes of TETs, which can facilitate decision-making and personalized therapy in clinical practice.

KEY POINTS: • A non-invasive diagnostic method that can predict the pathological risk status may be useful for pretreatment stratification and prognostic evaluation in TET patients. • DLRN demonstrated superior performance in differentiating the risk status of TETs when compared to the deep learning signature, radiomics signature, or clinical model. • The DeLong test and decision in curve analysis revealed that the DLRN was the most predictive and clinically useful in differentiating the risk status of TETs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chen, Feng, Xu, et al. Development and validation of a deep learning radiomics nomogram for preoperatively differentiating thymic epithelial tumor histologic subtypes. Eur Radiol. 2023. PMID: 37148352. doi:10.1007/s00330-023-09690-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。